AVEO Pharmaceuticals Inc. (AVEO)

2.86
NASDAQ : Health Technology
Prev Close 2.89
Day Low/High 2.76 / 2.92
52 Wk Low/High 1.86 / 4.15
Avg Volume 2.58M
Exchange NASDAQ
Shares Outstanding 121.50M
Market Cap 351.12M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO Oncology To Host Midyear Update Conference Call On August 10, 2015

AVEO Oncology To Host Midyear Update Conference Call On August 10, 2015

AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call on Monday, August 10, 2015, at 10:00 a.

AVEO Oncology Announces Exclusive Licensing Agreement With Pharmstandard For Tivozanib In Russia, Ukraine And CIS

AVEO Oncology Announces Exclusive Licensing Agreement With Pharmstandard For Tivozanib In Russia, Ukraine And CIS

AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group, the largest Russian pharmaceutical group ("Pharmstandard"), for the development,...

Interesting AVEO Call Options For September 18th

Interesting AVEO Call Options For September 18th

Investors in AVEO Pharmaceuticals, Inc. saw new options begin trading this week, for the September 18th expiration.

Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales

Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales

Exelixis plans to seek expanded approval for Cometriq to treat kidney cancer in early 2016.

AVEO Oncology Announces Additional Biomarker Analyses From BATON-CRC Tivozanib Study To Be Presented At The ESMO 17th World Congress On Gastrointestinal Cancer

AVEO Oncology Announces Additional Biomarker Analyses From BATON-CRC Tivozanib Study To Be Presented At The ESMO 17th World Congress On Gastrointestinal Cancer

AVEO Oncology (NASDAQ:AVEO) today announced that additional biomarker analyses from the BATON- ( Biomarker Assessment of Tivozanib in ONcology) CRC study will be presented at the European Society for Medical Oncology...

Today's Dead Cat Bounce Stock Is AVEO Pharmaceuticals (AVEO)

Today's Dead Cat Bounce Stock Is AVEO Pharmaceuticals (AVEO)

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "dead cat bounce" (down big yesterday but up big today) candidate

AVEO Announces FDA Update For Tivozanib In Colorectal Cancer

AVEO Announces FDA Update For Tivozanib In Colorectal Cancer

AVEO Oncology (NASDAQ:AVEO) today announced that it has received written feedback from the U.

Playing Biotechs with the House's Money

Here's how to lock in gains on risky small-cap biotechnology stocks.

AVEO Pharmaceuticals (AVEO) In A Perilous Reversal

AVEO Pharmaceuticals (AVEO) In A Perilous Reversal

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "perilous reversal" (up big yesterday but down big today) candidate

AVEO Announces Receipt Of European Regulatory Guidance Regarding Potential Marketing Authorization Application For Tivozanib

AVEO Announces Receipt Of European Regulatory Guidance Regarding Potential Marketing Authorization Application For Tivozanib

AVEO Oncology (NASDAQ:AVEO) today announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of...

AVEO Pharmaceuticals (AVEO) Is Today's Dead Cat Bounce Stock

AVEO Pharmaceuticals (AVEO) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "dead cat bounce" (down big yesterday but up big today) candidate

AVEO Oncology To Present At Jefferies 2015 Global Healthcare Conference

AVEO Oncology To Present At Jefferies 2015 Global Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 8:00 AM (ET) in New...

AVEO Oncology Announces New Corporate Headquarters In Cambridge, Massachusetts

AVEO Oncology Announces New Corporate Headquarters In Cambridge, Massachusetts

AVEO Oncology (NASDAQ:AVEO) today announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective today.

Perilous Reversal Stock: AVEO Pharmaceuticals (AVEO)

Perilous Reversal Stock: AVEO Pharmaceuticals (AVEO)

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "perilous reversal" (up big yesterday but down big today) candidate

AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a strong on high relative volume candidate

AVEO Oncology Announces Presentation Of Final Results Of Extension Study 902 And FDA Regulatory Feedback For Advancing Tivozanib In Renal Cell Carcinoma

AVEO Oncology Announces Presentation Of Final Results Of Extension Study 902 And FDA Regulatory Feedback For Advancing Tivozanib In Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment...

AVEO Oncology Reports First Quarter 2015 Financial Results

AVEO Oncology Reports First Quarter 2015 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2015.

Keith Ehrlich, Chief Financial Officer, AVEO Oncology

Keith Ehrlich, Chief Financial Officer, AVEO Oncology

AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S.

AVEO Oncology Announces Presentation Of AV-380 Preclinical Data In Cancer Associated Cachexia At 2015 Annual Meeting Of The American Association Of Cancer Research

AVEO Oncology Announces Presentation Of AV-380 Preclinical Data In Cancer Associated Cachexia At 2015 Annual Meeting Of The American Association Of Cancer Research

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company's potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a...

5 Stocks Under $10 Set to Soar Higher

5 Stocks Under $10 Set to Soar Higher

These under-$10 stocks are within range of triggering breakout trades.

AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

AVEO Pharmaceuticals (AVEO) Strong On High Relative Volume Today

Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a strong on high relative volume candidate

AVEO Pharmaceuticals (AVEO) Stock Higher Today After Analyst Upgrade

AVEO Pharmaceuticals (AVEO) Stock Higher Today After Analyst Upgrade

AVEO Pharmaceuticals (AVEO) stock is up after RBC Capital raised its rating to 'sector perform' from 'underperform.'

AVEO Oncology Reports Full Year 2014 Financial Results

AVEO Oncology Reports Full Year 2014 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2014.

AVEO Oncology Announces Presentation Of Phase 2 Study Analysis Showing Longer PFS With Tivozanib Compared To Bevacizumab In Low Serum NRP-1 Patients With Advanced CRC

AVEO Oncology Announces Presentation Of Phase 2 Study Analysis Showing Longer PFS With Tivozanib Compared To Bevacizumab In Low Serum NRP-1 Patients With Advanced CRC

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of final results, including a predefined biomarker analysis, from the BATON- ( Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase...

Regulators Want Drug Companies to Be Honest About FDA

Regulators Want Drug Companies to Be Honest About FDA

The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.

AVEO Oncology To Host Conference Call To Discuss Presentation Of Final Results And Biomarker Analysis From Phase 2 Study Of Tivozanib In Patients With Advanced Colorectal Cancer

AVEO Oncology To Host Conference Call To Discuss Presentation Of Final Results And Biomarker Analysis From Phase 2 Study Of Tivozanib In Patients With Advanced Colorectal Cancer

AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call and webcast on Friday, March 6, 2015, at 8:00 a.

AVEO To Present At The 33rd Annual J.P. Morgan Healthcare Conference

AVEO To Present At The 33rd Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33 rd Annual J.

Michael M. Needle, M.D., Chief Medical Officer (Photo: Business Wire)

Michael M. Needle, M.D., Chief Medical Officer (Photo: Business Wire)

AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N.

AVEO Receives Confirmation Of Eligibility For Submission Of A Tivozanib Marketing Authorization Application To The European Medicines Agency

AVEO Receives Confirmation Of Eligibility For Submission Of A Tivozanib Marketing Authorization Application To The European Medicines Agency

AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing...

Michael P. Bailey, President And Chief Executive Officer (Photo: Business Wire)

Michael P. Bailey, President And Chief Executive Officer (Photo: Business Wire)

AVEO Oncology (NASDAQ:AVEO) today announced that its Board of Directors has appointed Michael P.

TheStreet Quant Rating: D- (Sell)